Special Alerts:

[Posted 04/11/2007] Acorda Therapeutics and FDA informed healthcare professionals of changes to the CONTRAINDICATIONS and WARNINGS Sections of the product labeling for tizanidine (Zanaflex), a drug used to treat spasticity. In pharmacokinetic studies where tizanidine was coadministered with either fluvoxamine or ciprofloxacin (CYP1A2 inhibitors), the serum concentration of tizanidine was significantly increased and potentiated its hypotensive and sedative effects. Although there are no clinical studies evaluating the effects of other CYP1A2 inhibitors on tizanidine, coadministration of tizanidine with other CYP1A2 inhibitors (zileuton, other fluroquinolones, antiarrythmics, cimetidine, famotidine, oral contraceptives, acyclovir and ticlopidine) should be avoided. For more information visit the FDA website at: http://www.fda.gov/medwatch/safety/2007/safety07.htm#Zanaflex, http://www.fda.gov/medwatch/safety/2007/Zanaflex_DHCP_3-27-2007.pdf and http://www.fda.gov/medwatch/safety/2007/Zanaflex_PI_apr07.pdf.